IL326147A - שיטות לטיפול בסוכרת מסוג 1 - Google Patents

שיטות לטיפול בסוכרת מסוג 1

Info

Publication number
IL326147A
IL326147A IL326147A IL32614726A IL326147A IL 326147 A IL326147 A IL 326147A IL 326147 A IL326147 A IL 326147A IL 32614726 A IL32614726 A IL 32614726A IL 326147 A IL326147 A IL 326147A
Authority
IL
Israel
Prior art keywords
diabetes
methods
treating type
treating
type
Prior art date
Application number
IL326147A
Other languages
English (en)
Original Assignee
Provention Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provention Bio Inc filed Critical Provention Bio Inc
Publication of IL326147A publication Critical patent/IL326147A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL326147A 2023-07-27 2024-07-29 שיטות לטיפול בסוכרת מסוג 1 IL326147A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363515949P 2023-07-27 2023-07-27
US202363590883P 2023-10-17 2023-10-17
PCT/US2024/040020 WO2025024848A1 (en) 2023-07-27 2024-07-29 Methods for treating type 1 diabetes

Publications (1)

Publication Number Publication Date
IL326147A true IL326147A (he) 2026-03-01

Family

ID=92457137

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326147A IL326147A (he) 2023-07-27 2024-07-29 שיטות לטיפול בסוכרת מסוג 1

Country Status (6)

Country Link
KR (1) KR20260046157A (he)
CN (1) CN121568962A (he)
AU (1) AU2024299422A1 (he)
IL (1) IL326147A (he)
TW (1) TW202521153A (he)
WO (1) WO2025024848A1 (he)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
WO1991006287A1 (en) 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
AU2003236521A1 (en) 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
AU2006267090B2 (en) 2005-07-11 2013-03-07 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
MX2008015771A (es) 2006-06-14 2009-01-27 Macrogenics Inc Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida.
WO2022251253A1 (en) * 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes
EP4401773A4 (en) * 2021-09-13 2025-07-30 Provention Bio Inc METHODS AND COMPOSITIONS COMPRISING ANTI-CD3 ANTIBODIES AND DYRK1A INHIBITORS FOR THE TREATMENT OF DIABETES
IL314694A (he) * 2022-05-24 2024-10-01 Provention Bio Inc שיטות וקומפוזיציות למניעה או עיכוב של סוכרת מסוג 1
TW202448505A (zh) * 2023-03-01 2024-12-16 美商普泛森生技公司 用於治療第1型糖尿病的方法及組成物
TW202506177A (zh) * 2023-03-30 2025-02-16 美商普泛森生技公司 減少外源性胰島素使用之方法

Also Published As

Publication number Publication date
WO2025024848A1 (en) 2025-01-30
AU2024299422A1 (en) 2026-03-12
TW202521153A (zh) 2025-06-01
CN121568962A (zh) 2026-02-24
KR20260046157A (ko) 2026-04-06

Similar Documents

Publication Publication Date Title
IL288061A (he) תרכובות ושיטות לטיפול ב covid-19
IL308628A (he) שיטות לטיפול בסכרת מסוג 1
IL327282A (he) טיפולים חדש לכאב
EP4493175A4 (en) MIRDAMETINIB TREATMENT
DK4103178T3 (da) Fremgangsmåder til behandling af fabrys sygdom
FI3952858T3 (fi) Menetelmä kasvainten hoitamiseksi
LT4034122T (lt) Hiperfenilalaninemijos gydymo būdai
IL287130A (he) שיטות לטיפול בגרד
EP4487349A4 (en) AUTOMATIC LEARNING TO PREDICT BOLT TENSION
EP4521762A4 (en) PHOTOGRAPHY PROCESS
JP1735468S (ja) サングラス
EP4481051A4 (en) D-ALLULOSE-3-MODIFIED EPIMERASE
IL314050A (he) שיטת טיפול משולבת לקרצינומה הפטוצלולרית
EP3773546A4 (en) METHODS OF TREATMENT OF POST-PRRANDIAL HYPOGLYCEMIA
JP1750745S (ja) サングラス
IL311579A (he) שיטות ניבוי לטיפולים בסכרת מסוג 1
IL289824A (he) שיטות לטיפול בטרשת נפוצה
EP4592765A4 (en) PROCESSING CARTRIDGE
IL316776A (he) שיטות לטיפול במחלת פומפה
IL313079A (he) שיטות טיפול באמצעות lou064
EP4359114A4 (en) ENRICHMENT PROCESS
EP4021446A4 (en) COMPOUNDS FOR TREATING PAIN
EP4084767A4 (en) COMPOSITION FOR LIGHTENING OR WHITENING KERATIN MATERIALS
EP4745676A1 (en) PROCESSING CARTRIDGE
EP4743549A1 (en) DESULFURATION PROCESS